Passage Bio Stock Performance
| PASG Stock | USD 1.23 0.09 7.89% |
On a scale of 0 to 100, Passage Bio holds a performance score of 8. The company holds a Beta of 2.0, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Please check Passage Bio's daily balance of power, price action indicator, as well as the relationship between the expected short fall and value at risk , to make a quick decision on whether Passage Bio's historical price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVR - GuruFocus.com | 02/05/2024 |
2 | Passage Bio to Participate in UpcomingInvestor Conferences | 02/27/2024 |
3 | Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights | 03/04/2024 |
4 | Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program | 03/05/2024 |
5 | Passage Bio, Inc. Is Up 24.26 percent in One Week What You Should Know | 03/07/2024 |
6 | Acquisition by Cale Edgar B. of 203000 shares of Passage Bio at 1.5 subject to Rule 16b-3 | 03/15/2024 |
7 | Passage Bio Looks Good Stock Adds 5.4 percent in Session - Yahoo Movies UK | 04/17/2024 |
8 | Passage Bio to Present at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit | 04/22/2024 |
| Begin Period Cash Flow | 34.6 M |
Passage |
Passage Bio Relative Risk vs. Return Landscape
If you would invest 91.00 in Passage Bio on January 25, 2024 and sell it today you would earn a total of 32.00 from holding Passage Bio or generate 35.16% return on investment over 90 days. Passage Bio is currently generating 0.6848% in daily expected returns and assumes 6.5842% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Passage, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Passage Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Passage Bio, and traders can use it to determine the average amount a Passage Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.104
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PASG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.58 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Passage Bio is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Passage Bio by adding it to a well-diversified portfolio.
Passage Bio Fundamentals Growth
Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (24.62 M) | ||||
| Shares Outstanding | 61.61 M | ||||
| Price To Book | 0.75 X | ||||
| EBITDA | (96.42 M) | ||||
| Net Income | (102.06 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 26.29 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (78.26 M) | ||||
| Earnings Per Share | (1.86) X | ||||
| Market Capitalization | 70.24 M | ||||
| Total Asset | 150.54 M | ||||
| Retained Earnings | (594.47 M) | ||||
| Working Capital | 101.62 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
About Passage Bio Performance
To evaluate Passage Bio Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Passage Bio generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Passage Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Passage Bio market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Passage's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (0.92) | (0.87) |
Things to note about Passage Bio performance evaluation
Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Passage Bio is way too risky over 90 days horizon | |
| Passage Bio may become a speculative penny stock | |
| Passage Bio appears to be risky and price may revert if volatility continues | |
| Passage Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (102.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (78.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Passage Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Passage Bio to Present at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit |
- Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
- Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Passage Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.